The FDA approved Sanofi’s daily diabetes drug Toujeo Wednesday, but the new treatment does not appear to pack a profile that will pull payers or physicians away from Lantus to generic-free Toujeo.
Jumping into the multibillion-dollar market for biosimilar insulin products seemed like a no-brainer for Merck & Co., which is one of the world’s leaders in diabetes. But the company’s Lantus biosim ...
Sanofi Aventis launched a Lantus-branded “diabetes awareness campaign” featuring Paul and Mira Sorvino. The father-daughter acting duo, he of Goodfellas fame and she of Mighty Aphrodite, feature in ...
Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second complete ...
Merck announced that two Phase 3 studies evaluating MK-1293, an investigational, follow-on biologic insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes, achieved ...
The FINANCIAL -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on July 23 that following the review of the available evidence on Lantus (insulin glargine [rDNA] injection), the European ...
The day is here: Novartis’ Zarxio and Pfizer’s Inflectra are getting some company on the biosimilars market—and Sanofi’s Lantus is getting some unwanted competition in the basal insulin market, too.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results